Iris Roth
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Iris Roth
Iris Roth is recorded as COO at Zentalis Pharmaceuticals, Inc. (ZNTL). Zentalis Pharmaceuticals, Inc. reported in an 8-K filed February 13, 2023 that Iris Roth was appointed Chief Operating Officer, effective February 13, 2023. The proxy statement of Zentalis Pharmaceuticals, Inc. reports total compensation of $5,931,787 for Iris Roth in fiscal 2023, including a base salary of $287,423.
“On February 13, 2023, Zentalis Pharmaceuticals, Inc. (the "Company") publicly announced the appointment of Iris Roth, Ph.D. as Chief Operating Officer of the Company, effective as of February 13, 2023 (the "Commencement Date").”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
Start not stated–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Zentalis Pharmaceuticals, Inc.
Other people whose current roles at this company are on record from its filings.
- Julie Eastland CEO, Board Member
- Kimberly Blackwell, M.D. CEO
- David M. Johnson Chairman
- Scott Myers Chairman, Board Member
- Cam Gallagher CFO
- Vincent Vultaggio CFO, Chief Accounting Officer
- Iris Roth, Ph.D. COO
- James B. Bucher General Counsel
- David Johnson Board Member
- Enoch Kariuki Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Former Chief Operating Officer | $287,423 | $5,931,787 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.